Genomic and Epigenomic Biomarkers of Toxicology and Disease. Группа авторов

Чтение книги онлайн.

СКАЧАТЬ cell polarity and stemness-associated features in malignant pleural mesothelioma. Cancer Lett. 302 (2): 136–143.

      11 Cavalleri, T., Angelici, L., Favero, C. et al. (2017). Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease. PloS One 12 (5): e0176680.

      12 Cioce, M., Ganci, F., Canu, V. et al. (2014). Protumorigenic effects of miR-145 loss in malignant pleural mesothelioma. Oncogene 33 (46): 5319–5331.

      13 de Planell-Saguer, M. and Rodicio, M.C. (2011). Analytical aspects of microRNA in diagnostics: A review. Anal. Chim. Acta 699 (2): 134–152.

      14 De Santi, C., Melaiu, O., Bonotti, A. et al. (2017). Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism. Sci. Rep. 7 (1): 3140.

      15 Fassina, A., Cappellesso, R., Guzzardo, V. et al. (2012). Epithelial-mesenchymal transition in malignant mesothelioma. Mod. Pathol. Off. J. US Can. Acad. Pathol. Inc 25 (1): 86–99.

      16 Fennell, D. (2017). miR-16: Expanding the range of molecular targets in mesothelioma. Lancet Oncol. 18 (10): 1296–1297.

      17 Gee, G.V., Koestler, D.C., Christensen, B.C. et al. (2010). Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int. J. Cancer 127 (12): 2859–2869.

      18 Guled, M., Lahti, L., Lindholm, P.M. et al. (2009). CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes Chromosom. Cancer 48 (7): 615–623.

      19 Hata, A. and Lieberman, J. (2015). Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci. Signal 8 (368): re3.

      20 Ivanov, S.V., Goparaju, C.M., Lopez, P. et al. (2010). Pro-tumorigenic effects of miR-31 loss in mesothelioma. J. Biol. Chem. 285 (30): 22809–22817.

      21 Jean, D., Daubriac, J., Le Pimpec-Barthes, F., Galateau-Salle, F., and Jaurand, M.C. (2012). Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch. Pathol. Lab. Med. 136 (3): 277–293.

      22 Khodayari, N., Mohammed, K.A., Goldberg, E.P., and Nasreen, N. (2011). EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene. Cancer Gene. Ther. 18 (11): 806–816.

      23 Kirschner, M.B., Cheng, Y.Y., Badrian, B. et al. (2012). Increased circulating miR-625-3p: A potential biomarker for patients with malignant pleural mesothelioma. J. Thoracic Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 7 (7): 1184–1191.

      24 Kirschner, M.B., Kao, S.C., Edelman, J.J. et al. (2011). Haemolysis during sample preparation alters microRNA content of plasma. PloS One 6 (9): e24145.

      25 Kubo, T., Toyooka, S., Tsukuda, K. et al. (2011). Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 17 (15): 4965–4974.

      26 Liu, B., Peng, X.C., Zheng, X.L., Wang, J., and Qin, Y.W. (2009). MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer J. Int. Assoc. Study Lung Cancer 66 (2): 169–175.

      27 Luo, L., Shi, H.Z., Liang, Q.L., Jiang, J., Qin, S.M., and Deng, J.M. (2010). Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: A meta-analysis. Respir. Med. 104 (1): 149–156.

      28 Maki, Y., Asano, H., Toyooka, S. et al. (2012). MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma cells. Anticancer Res. 32 (11): 4871–4875.

      29 Matboli, M., Shafei, A.E., Ali, M.A. et al. (2019). Clinical significance of serum DRAM1 mRNA, ARSA mRNA, hsa-miR-2053 and lncRNA-RP1-86D1.3 axis expression in malignant pleural mesothelioma. J. Cell. Biochem. 120 (3): 3203–3211.

      30 Monaco, F., Gaetani, S., Alessandrini, F. et al. (2019). Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication. Cancer Lett. 463: 27–36.

      31 Mozzoni, P., Ampollini, L., Goldoni, M. et al. (2017). MicroRNA expression in malignant pleural mesothelioma and asbestosis: A pilot study. Dis. Markers 2017: 9645940.

      32 Mujoomdar, A.A., Tilleman, T.R., Richards, W.G., Bueno, R., and Sugarbaker, D.J. (2010). Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens. J. Thorac. Cardiovasc. Surg. 140 (2): 352–355.

      33 Munson, P.B., Hall, E.M., Farina, N.H., Pass, H.I., and Shukla, A. (2019). Exosomal miR-16-5p as a target for malignant mesothelioma. Sci. Rep. 9 (1): 11688.

      34 Muraoka, T., Soh, J., Toyooka, S. et al. (2013). The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer J. Int. Assoc. Study Lung Cancer 82 (3): 485–490.

      35 Pass, H.I., Goparaju, C., Ivanov, S. et al. (2010). hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res. 70 (5): 1916–1924.

      36 Price, A. (2011). What is the role of radiotherapy in malignant pleural mesothelioma. The Oncologist 16 (3): 359–365.

      37 Rascoe, P.A., Jupiter, D., Cao, X., Littlejohn, J.E., and Smythe, W.R. (2012). Molecular pathogenesis of malignant mesothelioma. Expert Rev. Mol. Med. 14: e12.

      38 Reid, G., Pel, M.E., Kirschner, M.B. et al. (2013). Restoring expression of miR-16: A novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 24 (12): 3128–3135.

      39 Robinson, B.W. and Lake, R.A. (2005). Advances in malignant mesothelioma. N. Engl. J. Med. 353 (15): 1591–1603.

      40 Santarelli, L., Staffolani, S., Strafella, E. et al. (2015). Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer J. Int. Assoc. Study Lung Cancer 90 (3): 457–464.

      41 Santarelli, L., Strafella, E., Staffolani, S. et al. (2011). Association of miR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PloS One 6 (4): e18232.

      42 Schramm, A., Opitz, I., Thies, S. et al. (2010). Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg: Off. J. Eur. Assoc. Cardiothorac. Surg. 37 (3): 566–572.

      43 Sempere, L.F. and Korc, M. (2013). A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol. Biol. 980: 43–59.

      44 Singh, A., Bhattacharyya, N., Srivastava, A. et al. (2019). MicroRNA-215-5p treatment suppresses mesothelioma progression via the MDM2-p53-signaling axis. Mol. Ther. J. Am. Soc. Gene Ther. 27 (9): 1665–1680.

      45 Tanaka, N., Toyooka, S., Soh, J. et al. (2013). Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells. Oncol. Rep. 29 (6): 2169–2174.

      46 Tomasetti, M., Staffolani, S., Nocchi, L. et al. (2012). Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin. Biochem. 45 (7-8): 575–581.

      47 Truini, A., Coco, S., Alama, A. et al. (2014). Role of microRNAs in malignant mesothelioma. CMLS 71 (15): 2865–2878.

      48 Ueno, T., Toyooka, S., Fukazawa, T., et al. (2014). Preclinical СКАЧАТЬ